Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study

ES Antonarakis; JM Piulats; M Gross-Goupil; J Goh; K Ojamaa; CJ Hoimes; U Vaishampayan; R Berger; A Sezer; T Alanko; Ronald de Wit; C Li; A Omlin; G Procopio; S Fukasawa; KI Tabata; SH Park; S Feyerabend; C G Drake; H Wu; P Qiu; J Kim; C Poehlein; JS de Bono

doi:10.1200/JCO.19.01638

Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study

ES Antonarakis, JM Piulats, M Gross-Goupil, J Goh, K Ojamaa, CJ Hoimes, U Vaishampayan, R Berger, A Sezer, T Alanko, Ronald de Wit, C Li, A Omlin, G Procopio, S Fukasawa, KI Tabata, SH Park, S Feyerabend, C G Drake, H WuP Qiu, J Kim, C Poehlein, JS de Bono

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

446 Citations (Scopus)

Original language	English
Pages (from-to)	395-405
Number of pages	11
Journal	Journal of Clinical Oncology
Volume	38
DOIs	https://doi.org/10.1200/JCO.19.01638
Publication status	Published - 2020

Research programs

EMC OR-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.19.01638

Cite this

Antonarakis, ES., Piulats, JM., Gross-Goupil, M., Goh, J., Ojamaa, K., Hoimes, CJ., Vaishampayan, U., Berger, R., Sezer, A., Alanko, T., de Wit, R., Li, C., Omlin, A., Procopio, G., Fukasawa, S., Tabata, KI., Park, SH., Feyerabend, S., Drake, C. G., ... de Bono, JS. (2020). Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study. Journal of Clinical Oncology, 38, 395-405. https://doi.org/10.1200/JCO.19.01638

@article{5ea7b35faea74aa7994f6d216636389b,

title = "Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study",

author = "ES Antonarakis and JM Piulats and M Gross-Goupil and J Goh and K Ojamaa and CJ Hoimes and U Vaishampayan and R Berger and A Sezer and T Alanko and {de Wit}, Ronald and C Li and A Omlin and G Procopio and S Fukasawa and KI Tabata and SH Park and S Feyerabend and Drake, {C G} and H Wu and P Qiu and J Kim and C Poehlein and {de Bono}, JS",

year = "2020",

doi = "10.1200/JCO.19.01638",

language = "English",

volume = "38",

pages = "395--405",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

}

Antonarakis, ES, Piulats, JM, Gross-Goupil, M, Goh, J, Ojamaa, K, Hoimes, CJ, Vaishampayan, U, Berger, R, Sezer, A, Alanko, T, de Wit, R, Li, C, Omlin, A, Procopio, G, Fukasawa, S, Tabata, KI, Park, SH, Feyerabend, S, Drake, CG, Wu, H, Qiu, P, Kim, J, Poehlein, C & de Bono, JS 2020, 'Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study', Journal of Clinical Oncology, vol. 38, pp. 395-405. https://doi.org/10.1200/JCO.19.01638

TY - JOUR

T1 - Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study

AU - Antonarakis, ES

AU - Piulats, JM

AU - Gross-Goupil, M

AU - Goh, J

AU - Ojamaa, K

AU - Hoimes, CJ

AU - Vaishampayan, U

AU - Berger, R

AU - Sezer, A

AU - Alanko, T

AU - de Wit, Ronald

AU - Li, C

AU - Omlin, A

AU - Procopio, G

AU - Fukasawa, S

AU - Tabata, KI

AU - Park, SH

AU - Feyerabend, S

AU - Drake, C G

AU - Wu, H

AU - Qiu, P

AU - Kim, J

AU - Poehlein, C

AU - de Bono, JS

PY - 2020

Y1 - 2020

U2 - 10.1200/JCO.19.01638

DO - 10.1200/JCO.19.01638

M3 - Article

C2 - 31774688

SN - 0732-183X

VL - 38

SP - 395

EP - 405

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -